 |
| |
 R&D Innovation & Strategies –Integrated Strategies To Over Come Pitfalls, Enhance Drug Discovery, Overcome Attrition & New Prediction Tools That Drive Clear Decision Making.
Focused Sirna Screens In Disease Based Assays - The Fast Track To A Target
Non-Invasive, Label-Free Assays - Getting the Most Out of your Targets and a Handle on Off-Target Effects
In Silico Innovation To Solve Drug Discovery – In-Silico Data, Data Mining, Predictive Modeling,
Exploring the impact & success rate of HTS Compound Library Screening.
Partnerships, Alliances & Outsourcing –Successful Partnerships, Managing Alliances, Balancing Conflicting Interests, Biotech Technology Platforms
Intergration of technologies & applications to bridge the gap between discovery, validation & development
How do you create intelligence from all this data, both structured and unstructured, across the entire value chain?
Streamline data processes and integration whilst improving early decision making and lowering attrition through the benefit of developing a dynamic workflows and an efficient infrastructure.
“An innovative approach”-lean/ 6-sigma efforts and organisational structures supporting lead optimisation."
Alternative cost effective screening methods and techniques to strengthen assay effectively. Bringing in-vitro screening for HTS, hit optimisation & lead optimisation together.
|
|
|
 |
|
| |
| |
2nd - 3rd March 2010
SPEAKERS INCLUDE
This 2 Day Forum Includes Over 40 Speakers In R&D & Drug Discovery And Attracts Over 150 Prominent Innovators Who Come To Learn More About Key Solutions & Innovation Being Provided To Their Industry, Network |
|
|
MARTIN HOFMANN-APITIUS
Head of Department
Bioinformatics, FRAUNHOFER SCAI |
|
|
FRANK SAMS DODD,
Ph.D., D.Sc.CEO,
Neurofit SAS & VP
BIONOMICS LTD. |
|
|
|
DR HARSUKH PARMER.
Global Head Early
Clinical Development
ASTRAZENECA |
|
|
|
DR ROD MACKENZIE
Head Knowledge
Management &
Computational Chemistry GenKyoTex |
| |
|
|
|
|
GDDIF 2010 LONDON
DISCOVERY TO DEVELOPMENT |
Presentations Addressed:
1. In silico ADMET
2. High content and cell-based assays
3. Early biomarkers for predicting safety
4. Target Discovery and Validation
5. Lead Generation, Optimisation & Characterisation
6. Clinically relevant animal models |
|
|
|
| |
Transforming R&D Innovation: Integrated Strategies To Improve Speed And Survival In Drug Discovery
Novel Methods To Identify Clinically Important New Treatments In R&D"
New And Evolving Business Models To Leverage The Global R&D Strategies” How Can Small & Medium-sized
Companies Form Risk Sharing Alliances To Reach Out Into The Global Market?
Challenges And Opportunities For Drug Discovery And Systems-biology
A perspective. – to hear about the latest developments in the use of systems approaches to drug discovery. ABCD - one step and beyond.
Aligned Alliances & Strategies- “Singing From The Same Hymn Sheet”
Aligned strategies,- leveraging logistical & operations pitfalls & risk. Maximizing Efficiencies to reduce time and cost whist keeping in line with ethical challenges, and strict safety
requirements |
|
|
|
|
|
|
